

Patient Wallet Card

It's always a good idea to be prepared; that's why we created this Patient Wallet Card. You or your Care Partner can carry it at all times, so if something happens, healthcare providers will have your important information quickly at hand.

This information is not designed to replace the advice of your healthcare provider. Please reach out to your healthcare team with any questions or concerns you may have.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, throughout.



Please remove this card and fold along the dotted lines.

Patient Wallet Card



Patient name:

EPKINLY start date:

Name of prescribing oncologist:

Office phone:

Carry this card with you at all times. Show this card to any healthcare provider involved in your care.

Call or see your oncologist or get emergency help right away if you have any of these symptoms:

Cytokine release syndrome (CRS)

- Fever of 100.4°F (38°C) or higher
- Dizziness or light-headedness
- Trouble breathing
- Chills
- Fast heartbeat
- Feeling anxious
- Headache
- Confusion
- Shaking (tremors)
- Problems with balance and movement, such as trouble walking

Immune effector cell-associated neurotoxicity syndrome (ICANS)

- Trouble speaking or writing
- Confusion and disorientation
- Drowsiness
- Tiredness or lack of energy
- Muscle weakness
- Shaking (tremors)
- Seizures
- Memory loss

Please see additional Important Safety Information before separating card or visit [EPKINLY.com](https://www.epkinly.com).

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

This patient is receiving EPKINLY—which may cause serious side effects, including **cytokine release syndrome (CRS)** and **immune effector cell-associated neurotoxicity syndrome (ICANS)**.

- If CRS or ICANS is suspected, please refer to sections 2.6, 5.1, and 5.2 of the EPKINLY full Prescribing Information
- Please follow up with the prescribing oncologist about the management of this event

For more information about EPKINLY, see full Prescribing Information at [EPKINLYhcp.com](https://www.epkinlyhcp.com).

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS (CONT'D)

To learn about adverse reaction management for EPKINLY, scan this QR code or visit [EPKINLYhcp.com](https://www.epkinlyhcp.com).



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536. Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064. EPKINLY is a registered trademark of Genmab A/S. ©2024 Genmab A/S and AbbVie. All rights reserved. 06/2024 COM-US-EPK-0000807

IMPORTANT SAFETY INFORMATION (CONT'D)

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. **The most common severe abnormal laboratory test results** include decreased white blood cells, decreased red blood cells, and decreased platelets.

In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. **The most common severe abnormal laboratory test results** include decreased white blood cells and decreased red blood cells.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see [Medication Guide](#), including Important Warnings.



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536.
Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.
EPKINLY is a registered trademark of Genmab A/S.
©2024 Genmab A/S and AbbVie. All rights reserved.
06/2024 COM-US-EPK-0000807

